背景介绍 TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies. 产品介绍 Recombinant Jurkat cell line constitutively expressing a full length human TIGIT (T cell Immunoreceptor with Immunoglobulin and ITIM domain; VSTM3), and a firefly luciferase gene under the control of nuclear factor of activator T cells (NFAT) response element. Both TIGIT and NFAT constructs have been stably integrated into Jurkat cells. TIGIT expression has been confirmed by Western Blot, and TIGIT-specific NFAT response has been validated using a TIGIT ligand, CD155 (PVR).